OCA $10.00 0%
0HGM.L $35.72 -2.9612%
AVDE $57.70 -0.543%
ASPA $10.55 0%
WFG $73.86 -0.4985%
0P0000KM1W.L $21 362.50 -0.0734%
0LCE.L $78.35 0.5724%
TTOO $0.29 1.0638%
6182.HK $0.19 0%
INTA $44.06 -0.6652%
TCS $2.83 -5.2013%
0757.HK $0.24 0%
CIS.BR $49.15 0%
ESC.L $31.00 0%
AEAC $10.13 0%
8072.HK $0.04 0%
3085.HK $25.86 0%
HTBX $2.38 0%
BBDC4.SA $15.46 0.3896%
KFY $47.45 -0.3988%
RDUS $10.08 0%
TIG $6.16 0%
BSCR $19.38 -0.3087%
ROLL $212.38 0%
LANC $209.51 -1.6131%
OPP $8.20 0.0488%
0HD0.L $24.83 0.0032%
PRP.L $67.00 0%
0428.HK $0.35 -5.4054%
0395.HK $0.02 0%
1399.HK $0.25 -1.9608%
0RP6.L $59.90 -1.642%
OSCR $6.94 -0.4304%
IRS $5.86 3.5336%
GAGG.L $4 157.50 0%
TQQQ $28.20 -2.8591%
CKN.L $2 995.00 0.335%
ENFAU $9.01 0%
PMX $7.98 -0.1252%
HTIBP $17.72 0.283%
0DTK.L $63.20 0.6369%
ALHGO.PA $46.00 0%
RAPT3.SA $8.68 1.2836%
VALT $48.13 -0.228%
JEL.L $460.00 0%
LRNZ $26.33 -2.0206%
GP $2.78 0%
ARG.NZ $1.10 0.4566%
RGO.L $0.70 0%
GII $55.44 -0.018%
CSQ $13.46 -0.7375%
JWAC $6.23 21.6797%
HPX $17.57 0%
TYG $28.71 0.6662%
STG.L $47.00 -10.4762%
QAT $19.37 -0.6667%
TU $20.34 -0.8772%
EBQ.L $48.00 0%
HEMO.L $2.23 4.7059%
SVFD $0.77 -8.3442%
0895.HK $2.67 -1.1111%
0209.HK $0.14 0%
ZSAN $0.56 0%
NAK $0.23 -0.1767%
ARRY $21.15 11.642%
0836.HK $18.54 -1.383%
ARKR $17.50 -0.7931%
DTEC.L $9.40 0.1065%
DX $10.96 -0.2277%
ALTM $62.35 0%
EUSB $43.16 -0.3923%
TRTX $5.38 -0.5545%
SNPR $9.30 0%
3968.HK $39.50 -1.9851%
EGAN $6.96 -2.2472%
EZJ.L $488.80 -0.8117%
0RTL.L $79.97 -0.3835%
HKOD.L $47.80 -0.2296%
3839.HK $1.66 -0.5988%
1145.HK $0.07 0%
3BSR.L $156.30 4.5135%
0JV3.L $18.92 -5.2104%
0ENN.L $48.60 0%
TSIBW $0.00 0%
KLDW $39.70 -0.2172%
GTE $5.58 0.0898%
PTICW $0.15 0%
PJP $75.68 -0.4754%
GEMD.L $24.45 -4.1176%
8483.HK $0.08 17.9105%
X1G.PA $212.91 -0.5427%
EDNCU $8.73 0%
0R8T.L $36.22 0%
G13.SI $1.11 -0.8929%
S08.SI $0.51 -0.9709%
SGOL $19.29 -0.0052%
2700.HK $0.35 0%
IGD $5.10 -0.098%
LSAK $3.57 9.5092%
Eng
Логотип
Eng
Лого

Poolbeg Pharma PLC POLB.L

$7.55

На 18:04, 12 мая 2023

Ключевые показатели

  • Marketcap

    35250000.00000000

  • week52high

    11.14

  • week52low

    4.00

  • Revenue

  • P/E TTM

    0

  • Beta

    0.00000000

  • EPS

    -0.01000000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    30 мар 2023 г. в 09:00

Описание компании

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class intranasally administered RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек